Drug Profile
P 30 extract
Latest Information Update: 31 Aug 2007
Price :
$50
*
At a glance
- Originator Phytopharm
- Class Antihyperglycaemics; Phytotherapies
- Mechanism of Action Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 19 Nov 1999 Phytopharm is pursuing discussions with potential partners for P 30
- 29 Aug 1996 Preclinical development for Diabetes mellitus in United Kingdom (PO)